These data highlight the relevance of examining TGF--independent SMAD2/3 signaling mechanisms as a therapeutic axis to relieve NK cell suppression and promote antitumor immunity.
INTRODUCTION
Natural killer (NK) cells play a well-established role in protecting against tumor initiation and metastasis and are the focus of numerous clinical attempts to harness their unique antitumor functions (1, 2) . Several biological factors directly suppress or limit NK cell function through a range of mechanisms in the context of malignant disease. These include tumor-derived metabolites such as adenosine (3, 4) , enzymes such as indoleamine 2,3-dioxygenase-1 (IDO1 or IDO) (5) , an increase in the abundance of cytokine-inducible Src homology 2 (SH2)-containing protein (CIS, encoded by Cish) (6) , a reduction in the abundance of the antiapoptotic proteins Bcl2 and Mcl1 (7) (8) (9) , modulation of the abundance of the activating receptor natural killer group 2D (NKG2D) (10) , expression of inhibitory receptors for major histocompatibility complex class I (MHC-I) (11, 12) , and transforming growth factor- (TGF-) (13, 14) .
TGF- is a secreted protein that has three different isoforms: TGF-1, TGF-2, and TGF-3. These isoforms are expressed in different tissues, with TGF-1 being the most abundant and potent modulator of the immune system (15) . TGF-1 is a pleiotropic cytokine produced by several cell subtypes [including tumor cells, regulatory T (T reg ) cells, stromal fibroblasts, and various myeloid cell subsets] and is an important suppressor of the antitumor functions of NK cells in experimental tumor models (13, 16, 17) . TGF-1 reduces NK cell priming and activation, including both cytotoxicity and cytokine production, by suppressing the mammalian target of rapamycin (mTOR) pathway (13, 18) . Consistent with this, a previous study demonstrated that anti-TGF--neutralizing antibodies increase NK cell effector functions in vitro and in vivo (19) .
TGF- receptor I (TGF-RI) and TGF-RII are transmembrane receptors associated with serine and threonine kinases that, upon ligand binding, mediate the phosphorylation of the SMAD family of transcription factors (20) . Although TGF- is the best-described inducer of this pathway, other factors [including activin-A, activin-B, myostatin (GFF8), GDF11, nodal, and bone morphogenetic proteins (BMPs), which play a critical role in bone and muscular development] can also stimulate the phosphorylation of SMAD3 and SMAD3 (collectively referred to as SMAD2/3) (21) (22) (23) . Activin-A binds to a set of receptors (including ALK4, ALK7, ActRIIA, and ActRIIB) that are distinct from those used by the TGF- isoforms (22) . Activin-A and its receptor dimer comprising ALK4 and ACVR2A or ACVR2B play a critical role in muscular development (23) and can be produced in large amounts by dendritic cells (DCs) or after acute inflammation (24, 25) .
Although TGF- signaling is a critical step in the differentiation of naïve CD4 + T cells into CD4 + Foxp3 + T reg cells, activin-A can also induce Foxp3 expression and promote the generation of T reg cells (26, 27) . In breast and ovarian cancer cells, activin-A signaling induces the epithelial-mesenchymal transition (EMT), a malignant cellular reprogramming that is characteristic of TGF- signaling (28, 29) . In addition, activin-related genes are increased in expression during breast cancer cell EMT (30) . High circulating amounts of activin-A are associated with tumor progression and poor prognosis in patients with lung cancer (31) . In addition, activin signaling reprograms macrophages into protumorigenic subsets that promote skin carcinogenesis (32) . The biological activity of activin-A is inhibited by an endogenous inhibitor known as follistatin (FST) and also at the cell surface by TGFBR3 (betaglycan) (33) . Studies have shown a correlation between reduced FST abundance and lower survival rates among patients with breast cancer and cutaneous melanoma (34, 35) . Similarly, low expression of Tgfbr3 is prognostic of poor survival in renal cell carcinoma (36) . Previous work showed that DCderived activin-A reduced the activation of peripheral blood human NK cells and their production of cytokines (37) . Although previous studies have hinted at the involvement of alternative SMAD2 or SMAD3 pathways in regulating human NK cell function, the precise mechanism and influence on NK cell biology are still to be elucidated.
The broader effect of TGF- signaling on group 1 innate lymphoid cells [consisting of conventional NK (cNK) cells and type 1 innate lymphoid cells (ILC1) (38) ] was demonstrated in the salivary gland and has generated renewed interest in the precise effect of TGF- on NK cell functions within the tumor microenvironment (39) . We previously identified a unidirectional reprogramming of cNK cells into ILC1-like cells that was driven by TGF- in the tumor microenvironment. Transgenic mouse models with ablated or constitutive TGF- signaling specifically in NKp46 + cells had reduced numbers of ILC1s and cNK cells, respectively. TGF- signaling also drives cNK cells to acquire a transitional ILC1-like phenotype both in vitro and in vivo by reducing the abundance of the transcriptional factor Eomesodermin (or Eomes) and increasing the abundance of tissue residency-related markers, such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and the collagen-binding protein integrin -1 (CD49a) in the tumor microenvironment (14) . A population of NKp46 +
CD49a
+ cells was still observed in the tumor microenvironment of NKp46 cre/+ TgfbR2 fl/fl mice, which suggests that a minor TGF--independent pathway for ILC1-like differentiation may exist. Here, we showed that activin-A stimulates an alternative SMAD signaling pathway that suppressed NK cell metabolism and cytotoxicity, ultimately inducing an increase in the abundance of tissue residency markers on NK cells.
RESULTS

Functional activin-A receptor expression on NK cells
Receptors for activin-A are classified as type 1 [ACVR1B (also known as ALK4) and ACVR1C (also known as ALK7)] and type 2 (ACVR2A and ACVR2B) receptors (40) . Human NK cells are reported to express mRNA for activin-A receptors (ALK4, ACVRIIA, and ACVRIIB) and potentially respond to activin-A (37 1A) and consistent with our previous report (13) . However, we failed to detect mRNAs corresponding to the receptors ACVR2A, ACVR2B, and ACVR1C in these NK cell subsets ( fig. S1 ).
A challenge in the field of TGF- research is the highly conserved homology of this cytokine between species (44). Because of the presence of bovine TGF- in conventional media containing fetal calf serum (FCS) ( fig. S2 ), in our in vitro assays, we used medium free from animal-derived components to compare the effects of recombinant TGF- versus activin-A. Using recombinant activin-A (rActivin-A), we observed that purified mouse NK cells exhibited increased amounts of phosphorylated SMAD2/3 in a concentrationdependent manner but not to the same degree as that found in cells treated with recombinant TGF- (rTGF-1) (Fig. 1, B and C) . Similarly, both rTGF-1 and rActivin-A (particularly at the highest concentration tested) inhibited NK cell proliferation in response to interleukin-15 (IL-15) (Fig. 1, D and E). We found that neither ligand induced NK cell death (fig. S3) (7) but rather suppressed the rate at which the NK cells divided (Fig. 1, D and E). These results suggest that NK cells responded to activin-A, albeit with less extensive SMAD2/3 phosphorylation than that induced by TGF- and with less of an effect on proliferation.
Inhibition of proliferation is a notable consequence of TGF- signaling in NK cells and is directly linked to the inhibition of metabolism mediated by mTOR (13) . To relate these changes to cellular metabolism, we measured the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of wild-type (WT) and TgfbR2-deficient NK cells in response to rActivin-A or TGF- (Fig. 1, F and G) . Unexpectedly, TgfbR2-deficient NK cells displayed at least twofold higher basal glycolysis (ECAR) and oxidative phosphorylation (OCR) compared to WT cells, suggesting that they exhibited constitutively enhanced metabolism in vitro. Although rTGF-1 was unable to inhibit ECAR and OCR in TgfbR2-deficient NK cells, it completely suppressed metabolism in WT NK cells (Fig. 1, F and G) . We found that rActivin-A inhibited both of these parameters in both WT and TgfbR2-deficient NK cells and that this effect was maximal at the lower concentration of rActivin-A, suggesting that minimal SMAD2/3 phosphorylation was required to suppress metabolism (Fig. 1, B and C) . Together, these results suggest that the ALK4 pathway inhibits cellular metabolism in murine NK cells.
Activin signaling drives an increase in tissue residency marker abundance on NK cells
Lymphocytic tissue residency is characterized by decreased proliferation and the expression of tissue residence markers, such as the collagen-binding receptor CD49a (also known as ITGA1 and VLA-1), which functions as a cellular anchor (45) . Parabiosis experiments demonstrated that tissue-resident Eomes neg CD49a + NK cells, also known as ILC1s, are unable to migrate between parabiotic mice, whereas conventional Eomes + CD49a neg NK cells (cNK) migrate freely (46) . We previously showed that rTGF-1 simultaneously increases CD49a cell surface abundance and reduces Eomes abundance in cNK cells in vitro. In addition, although TGF-R2-deficient NKp46 + cells are completely unresponsive to rTGF-1 in vitro, CD49a is still detectable on a subset of these cells in vivo (14) .
To investigate whether cNK to ILC1-like differentiation (characterized by reduced Eomes and increased CD49a abundance) could be induced by rActivin-A similarly to rTGF-1, we cultured highly purified (99 to 100% purity) splenic cNK cells ( (Fig. 2, A to D) . We identified similar patterns of protein expression between WT NK cells stimulated with either rTGF-1 or rActivin-A and RII FL cells stimulated with rActivin-A, but not rTGF-1. Unexpectedly, rActivin-A was as efficacious as rTGF-1 at increasing the surface abundance of CD49a on WT NK cells and, unlike TGF-, also acted upon TGF-R2-deficient NK cells (Fig. 2 , A and D to F). We also identified a number of proteins that were consistently reduced in abundance in WT NK cells stimulated with either rTGF-1 or rActivin-A and in RII FL cells that were stimulated with rActivin-A but not rTGF-1 (Fig. 2, A to D) , including the proliferation marker Ki67, stathmin (STMN1), and the DNA binding protein IKZF1 (or Ikaros), an important transcriptional factor that maintains NK cell maturation and function (47) .
We next addressed whether signaling induced by the simultaneous combination of activin-A and TGF- could maximize the signaling effects of the SMAD2/3 pathway in NK cells using the measurement of CD49a and Ikzf1 abundance as a readout. We performed in vitro combinatorial experiments with both stimuli in different concentrations to measure synergistic effects on CD49a and Ikzf1 expression. The abundance of CD49a was increased by different concentrations of activin-A in WT and TGF-RII-deficient NK cells and by TGF-1 in WT cells ( fig. S4A ), consistent with our earlier data (Fig. 2, E and F) ; however, the addition of rTGF-1 at different concentrations was unable to synergistically increase CD49a abundance in activin-A-treated WT cells ( fig. S4B ). Corroborating our global proteomics data, we also observed by intracellular fluorescence-activated cell sorting (FACS) ) or their respective littermate control mice were cultured in medium containing rIL-15 (50 ng/ml) with or without the indicated concentrations of rActivin-A or rTGF-1 for 48 hours. Cell surface CD49a expression (E and F) was determined by flow cytometry analysis, with data represented as histograms (E) or as MFI (F) for the indicated stimulation condition. Error bars represent the SEM, and each data point/histogram represents one independent biological replicate. Unpaired t tests were used for comparative statistical analysis. ***P < 0.001.
Activin-A modulates NK cell-mediated killing
A previous study showed that rTGF-1 inhibits NK cell cytotoxicity in vitro (13) . Similarly, the constitutive activation of TGF-R1 in NKp46 + cells completely abolishes the in vivo killing potential of NK cells (14) . In addition to being a critical survival factor (8, 9) , IL-15 induces the production of granzyme B (GrzB) in NK cells (48) . To test whether activin signaling also limited NK cell cytotoxicity, we cultured WT and TGF-RII-deficient NK cells with IL-15 and exposed them to either TGF- or activin. As expected, rTGF-1 reduced the amount of GrzB in WT NK cells, whereas rActivin-A modestly reduced its abundance in both WT and TGF-RII-deficient NK cells (Fig. 3, A and B) . Consistent with this observation, we found that rTGF-1 suppressed the NK cell-mediated killing of B16F10 melanoma cells to a greater extent than did rActivin-A (Fig. 3C) . These results show a subtle but previously uncharacterized role for activin in suppressing NK cell cytotoxicity independently of canonical TGF- signaling.
Distinct effects of activin and TGF- signaling on cytokine secretion by NK cells
To further assess whether the activin and TGF- signaling pathways had divergent effects on NK cell function, we assessed the cytokines secreted by purified WT or TgfbR2 fl/fl NK cells after stimulation for 48 hours with rIL-15 in the presence or absence of rActivin-A, rTGF-1, rIL-12, or rIL-18. We found that TGF- impaired the secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) in response to IL-12 and IL-18, whereas activin-A had no such effect (Fig. 4A) . Interferon- (IFN-) production by NK cells is markedly increased in response to IL-12 or IL-18, which was not affected by either activin-A or TGF-. Despite being phenotypically similar to WT NK cells, TGF-RII-deficient NK cells produced notably more IFN- than did WT cells, suggesting that they were more activated in the absence of TGF- signaling in vivo ( Fig. 4B ; similar to the higher basal metabolism indicated by higher OCR observed in Fig. 1G ). To test whether these findings could be corroborated with human NK cells, human cord blood-derived NK cells were cultured for 48 hours in the same concentrations of IL-12, IL-15, and IL-18 that were used to treat mouse NK cells and in a range of activin-A or TGF- concentrations. All of the TGF-1 concentrations tested resulted in suppression of IFN- secretion in response to IL-12 or IL-18 stimulation, whereas only the highest concentration of activin-A used had the same effect (Fig. 4C ). This result not only supports a previous report (37) that demonstrated similar effects in human peripheral blood-derived NK cells but also reveals that not all aspects of activin-A or TGF- signaling are conserved between mouse and human cells.
Targeted inhibition of activin signaling in NK cell-dependent in vivo models of melanoma
Using clinical-grade FST (98% homologous between mouse and human), which is specific to activin-A and not to other BMP family members ( fig. S5 ), we first tested whether it was possible to therapeutically enhance the highly NK cell-dependent immune response against the B16F10 melanoma model (8, 49) . FST was administered to tumor-bearing mice according to the manufacturer's recommendations and was compared to a TGF-1/2/3-neutralizing antibody (clone 1D11.16.8) and the TGF-RI kinase inhibitor galunisertib (also known as LY2157299), which has been validated for in vivo use (50) (51) (52) . These experiments revealed that, similar to TGF- blockade, FST statistically significantly reduced the number of lung metastases; however, no additive benefit was observed when both agents were combined (Fig. 5, A and B) . In a different approach, we compared the effect of FST in the high B16F10 burden model using RII FL mice or WT littermate controls and found that only FST statistically significantly reduced lung metastases (Fig. 5C) ; a more enhanced effect was observed when TGF-RII was conditionally deleted in the NK cells (RII FL mice) (Fig. 5C ). These results suggest that in vivo inhibition of activin-A could improve tumor rejection by enhancing the innate effector functions of NK cells. TGF- signaling in NK cells induces the increased abundance of ILC1-like markers in vivo (14, 39) . Although the conditional deletion of the gene encoding TGF-RII in NKp46 + cells suggested that this increased abundance of ILC1-like markers could be largely prevented in vivo, alternative stimuli of the SMAD2/3 pathway likely compensated for the lack of TGF- signaling. Murine cytomegalovirus (MCMV) infection was previously described to induce the increased abundance of ILC1-like molecules (e.g., TRAIL, CD49a, and CD69) (53) on salivary gland NK cells in a TGF--like manner (39) . To assess whether these MCMV-induced changes in ILC1-like markers (e.g. CD49a, CD69, or TRAIL) could be therapeutically prevented, we treated MCMV-infected mice with FST, a TGF--neutralizing antibody, or a combination of both. None of the treatments prevented the increased expression of CD49a, CD69, or TRAIL on NKp46 + cells in either the liver or salivary glands of the mice on day 6 after infection ( fig. S6 ). We also did not observe any statistically significant differences in viral loads in the spleen, liver, or lungs of mice from the different treatment groups 6 days after infection ( fig. S7 ). These data suggest that neither activin-A or TGF-1 changed NK cell programs induced during MCMV infection, nor did they impact on viral replication during acute infection. Thus, unlike for tumor immunotherapy, blockade of activin may not be relevant in the context of viral pathogenesis.
Validation of activin signaling in human NK cells
To further validate whether activin-A signaling was conserved between human and mouse NK cells, we examined key signal transduction pathways and markers of ILC1 cells and NK cells. Human cord blood-derived NK cells were purified and activated in medium containing donor-matched serum and IL-15, and a neutralizing antibody against either mouse or human TGF-1/2/3 was used for 5 days to remove any TGF- present in the serum. The cells were then exposed to rIL-15, rActivin-A, rTGF-1, or combinations of these cytokines for different times. Assessment of the phosphorylation of signaling molecules revealed efficient phosphorylation of SMAD2/3 by either rActivin-A or rTGF-1 irrespective of whether IL-15 was . The unpaired t test was used to compare differences between groups of mice as indicated. *P < 0.05, **P < 0.01, and ***P < 0.01. Fig. 6A and fig. S8A ). Consistent with our previous report (13), we observed that IL-15-induced phosphorylation of signal transducer and activator of transcription 5 (STAT5) was independent of SMAD2/3 phosphorylation (in response to either activin-A or TGF-1) (Fig. 6B and fig. S8B ). However, both activin-A and TGF-1 suppressed the IL-15-induced phosphorylation of AKT and S6K (Fig. 6, C and D, and fig. S8 , C and D), consistent with our earlier findings (Fig. 1, F and G) and our previous work on mouse NK cell metabolism (13) . Last, we also examined whether activin-A signaling induced the increased abundance of ILC1 markers on human NK cells, similarly to what we observed with mouse NK cells (Fig. 2) . We cultured human cord blood-derived NK cells for 7 days with IL-15 in the presence of either rActivin-A or rTGF-1. Consistent with our findings from 
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Fig. 6. Conserved features of activin signaling in human NK cells. (A to H)
Human NK cells were isolated from fresh cord blood (three different donors) and primed in rIL-15 for 48 hours. The cells were then washed, starved for 4 hours in animal component-free medium at 37°C, and stimulated in medium containing rIL-15 (10 ng/ml) with or without the indicated concentrations of rActivin-A or rTGF-1 for 1 hour. The relative abundances of pSMAD2/3 (A), pSTAT5 (B), pAKT (C), and pS6 (D) were determined by flow cytometry analysis and reported as MFI. (E to H) A portion of the same cord blood NK samples was cultured separately for 7 days in the presence of rIL-15 (50 ng/ml) with or without the indicated concentrations of rActivin-A or rTGF-1. The cells were then surface-stained with anti-CD49a antibody (E) and intracellularly stained with anti-Ki67 (F), anti-GrzB (G), and anti-Eomes (H) antibodies, and their relative MFIs were analyzed by flow cytometry. Data are means ± SEM. Each dot on the graphs represents one independent technical replicate (with three technical replicates for each of the three donors). The unpaired t test was used for comparative statistical analysis. *P < 0.05, **P < 0.01, and ***P < 0.001. experiments with mouse NK cells, we found that the cell surface abundance of CD49a was increased in a concentration-dependent manner by both rActivin-A and rTGF-1 (Fig. 6E and fig. S8E ), whereas there was a corresponding reduction in the amounts of GrzB and Ki67 (Fig. 6, F and G, and fig. S8 , F and G). We also found that rActivin-A was sufficient to reduce the abundance of Eomes in human NK cells (Fig. 6H and fig. S8H ). Last, similar to our findings from experiments with mouse NK cells (Fig. 1, D and E) , we found that both rActivin-A and rTGF-1 reduced the expansion of human NK cells by suppressing their proliferation rate (reduced mean division number) (Fig. 7, A and B) . These findings indicate that the regulation of NK cell biology by activin-A signaling is likely conserved between humans and mice.
DISCUSSION
Immune checkpoint inhibitors have revolutionized cancer therapy by reinvigorating cytotoxic lymphocytes to kill malignant cells. NK cells have an innate ability to detect cellular transformation and are key to cancer immunosurveillance, particularly in the prevention of metastasis (1) . An understanding of the tumor microenvironment and how tumor cells evade detection by NK cell is now emerging and has stimulated great interest in the therapeutic targeting of such pathways (54) . We previously revealed an immune evasion mechanism in which tumors exploit the TGF- signaling pathway to differentiate cNK cells (CD49a neg ) into ILC1-like subsets (CD49a + ) and, in doing so, reduce their intrinsic antitumor functions (14) . An earlier study described a similar differentiation process in salivary gland NK cells (39) . Both of these studies used the conditional deletion of the gene encoding TGF-RII in NK cells (NKp46 The concentration-dependent effect of activin-A on WT NK cells was exemplified in experiments examining SMAD2/3 phosphorylation, Ki67 and GrzB abundances, and impaired killing of B16F10 melanoma cells. However, NK cell metabolism and ILC1-related gene expression appeared to be maximally altered at the lowest concentrations of activin-A, highlighting the differential sensitivity of certain NK-suppressive pathways to activin-A signaling. Despite this, endogenous amounts of activin-A appeared to be sufficient to suppress NK cell activity because the therapeutic administration of FST reduced lung metastases in a NK cell-dependent melanoma model. Together, our results reveal a previously unappreciated capacity for activin-A to regulate NK cell differentiation, thereby ultimately facilitating the ability of tumors to evade NK cell-mediated immune surveillance in a TGF--independent manner. Our findings suggest that combinatorial therapies targeting activin signaling may result in greater prevention of cNK-ILC1-like cell differentiation in the tumor microenvironment (and the associated suppression of cellular metabolism and effector function) and subsequently enhance innate antitumor immune control.
MATERIALS AND METHODS
Mice
TGF-RII-deficient NK cells were isolated from NKp46 cre/wt
TgfbR2 fl/fl mice, which were generated by crossing NKp46-iCre mice (55) with TgfbR2 LoxP mice (56) as previously described (13, 14) . WT NK cells were isolated from the corresponding littermate controls (NKp46 wt/wt TgfbR2 fl/fl ). All mice were on a C57BL/6J background Freshly isolated human cord blood-derived NK cells were labeled with a division-tracking dye and cultured in the presence of rIL-15 (50 ng/ml) and in the presence or absence of the indicated concentrations of rTGF-1 or rActivin-A. For each condition, the total number of live cells was enumerated at 24-hour intervals (A), and the population average division number was calculated (B). Results are from one donor and are representative of three independent biological replicates. Data are means ± SD of three technical replicates. Two-way ANOVA tests were used for comparative statistical analysis. *P < 0.05 and ***P < 0.001.
and were bred and maintained at the Walter and Eliza Hall Institute of Medical Research (WEHI). For MCMV infections, BALB/C mice were acquired from the Animal Research Centre (Perth) and housed in the Bioresources Department of the Harry Perkins. All experiments were performed using cells from an age-and sex-matched cohort of mice (age range, 8 to 12 weeks). Cohort sizes are described in each figure legend to achieve statistical significance. No biological replicate was excluded on the basis of pre-established criteria. All experiments were approved by the WEHI and Harry Perkins Institute of Animal Ethics Committees.
Reagents
Reagents or antibodies targeting the following human (h) or murine (m) epitopes were purchased from BioLegend: 7-aminoactinomycin D (7-AAD), mCD3 (145-2C11), mCD19 (6D5), mCD49b (DX5 and HM2), mCD62L (MEL-14), mDNAM-1 (10E5), mF4/80 (BM8), mLy6G (1A8), mNK1.1 (PK136), mNKp46 (29A1.4), streptavidin-FITC (fluorescein isothiocyanate), and mTCR- (H57-597). Reagents or antibodies targeting the following epitopes were purchased from eBioscience: mCD49b (DX5), hEomes (WD1928), mEomes (Dan11mag), mGranzyme B (NGZB), hGranzyme B (GB11), mTCR- (H57-597), and mTRAIL (N2B2). Reagents or antibodies targeting the following epitopes were purchased from BD Biosciences: Akt(pS476) (M89-61), fixable viability stain, mNK1.1 (PK136), Ki67 (B56), SMAD2(pS465/S467)/SMAD3(pS423/pS425) (I72-670), and STAT5(pY694) (47/Stat5(pY694)). Antibody targeting pS6(pS235/S236) (#2211) was purchased from Cell Signaling Technology. Antibodies targeting mCD45.2 (30F11), mCD49a (REA493), hCD49a (TS2/7), mCD69 (H1.2F3), and hNKp46 (9E2) were purchased from Miltenyi Biotec. The MACSXpress Human NK Cell Isolation Kit (Miltenyi Biotec) was used for the negative selection of cord blood NK cells. To detect intracellular Eomes, GrzB, and Ki67, surface-stained cells were fixed and permeabilized with the Intracellular Fixation and Permeabilization Buffer Set and stained with antibodies in 1× Permeabilization Buffer (eBioscience). Cell numbers were calculated with BD Liquid Counting Beads (BD Biosciences).
NK cell isolation and culture conditions
Mice were sacrificed, and spleens were harvested and prepared for flow cytometry as previously described (49) . Spleen homogenates were incubated in Fc blocking buffer (2.4G2 antibody) on ice for 15 min and then pre-enriched by lineage (Lin: CD3, CD19, CD49a, F4-80, Ly6G, TCR) biotin-antibody cocktail staining, which was followed by incubation with MagniSort Streptavidin Bead Negative Selection (eBioscience). The remaining fraction of cells was stained with streptavidin-FITC, and NK cells (7-AAD − Lin − CD45 + NK1.1 + NKp46 + CD49b + ) from transgenic or WT mice were then sorted with a BD FACSAria III cell sorter (BD Biosciences) to achieve a final cell purity of 99 to 100%. Human cord blood NK cells were isolated by negative selection with a final cell purity of 95 to 99% using the MACSXpress Human NK Cell Isolation Kit (Miltenyi Biotec). After sorting or negative selection, mouse or human NK cells were stained with CellTrace Violet (Invitrogen) and plated at a density of 25,000 cells per well in V bottom 96-well plates (Greiner Bio-One) containing RPMI 1640 supplemented with 10% FCS, 1% sodium pyruvate (Gibco), 1% GlutaMAX (Gibco), 10 mM Hepes, 0.1% 2-mercaptoethanol (Gibco), and 1% penicillin/streptomycin in the presence or absence of human rIL-15 (Miltenyi Biotec), human/ mouse rActivin-A (R&D Systems), mouse rTGF-1 (eBioscience), or human rTGF-1 (PeproTech) at the concentrations and for the times indicated in the figure legends. Culture conditions were maintained at 37°C and 5% CO 2 . Intracellular staining of phosphorylated signaling proteins was performed using antibodies against pAkt, pSMAD2/3, pS6, and pSTAT5 after endpoint fixation and permeabilization with Lyse/Fix and Perm III buffers (BD Biosciences). Data were acquired with an LSR Fortessa flow cytometer (BD Biosciences). Flow cytometric analysis was performed with FlowJo software (TreeStar). For proliferation and viability assays, fresh human and murine NK cells were incubated with 5 M CellTrace Violet (Thermo Fisher Scientific) according to the manufacturer's instructions, and 8 × 10 3 labeled cells were seeded into 96-well round bottom plates in complete medium containing cytokines at the concentrations and for the times indicated in the figure legends. Routine time points were assessed on a BD FACSVerse cytometer (BD Biosciences), and survival and division numbers were determined using the precursor cohort-based method (57, 58) , as previously described for NK cell kinetics (7). 
In vitro cytokine secretion assays
Target:effector cell cocultures
Sorted and expanded NK cells (as described earlier) were used to perform standard 4-hour cytotoxicity assays using calcein-AM (acetoxymethyl) B16F10 melanoma cells labeled with calcein-AM (BD Biosciences), as previously described (6) . Briefly, NK cells from mice of the genotypes indicated in the figure legends were cultured overnight (for 16 hours) in the presence of rTGF-1 or rActivin-A at the indicated concentrations and in the presence of rIL-15 (50 ng/ml). The NK cells were then seeded at the given ratios with calcein-AM-labeled target cells in complete NK cell medium (phenol red-free RPMI 1640 containing 10% FBS, -mercaptoethanol, GlutaMAX, and sodium pyruvate). After 4 hours of coculture, supernatants were transferred to opaque 96-well plates (Costar), and fluorescence emission was measured with an EnVision microplate reader (PerkinElmer). Cytotoxicity data were expressed as the percentage lysis relative to the spontaneous (target cells alone) and maximum release (treated cells; 1% Triton X-100, Sigma-Aldrich). In some experiments, melanoma cells were cultured on round glass coverslips and cocultured overnight in 24-well plates with purified NK cells in the indicated culture conditions. NK cell preparation for proteomics NK cells were sorted from the spleens of RII FL or WT mice and expanded for 7 days in rIL-15 (50 ng/ml) in RPMI 1640 medium containing 10% FCS supplemented with neutralizing TGF-1/2/3 antibody (1D11.16.8). Cells were then washed three times with icecold phosphate-buffered saline (PBS) and starved in serum-free medium for 4 hours, and then 5 × 10 6 cells per replicate/culture condition were cultured in medium containing rIL-15 (10 ng/ml) with rTGF-1 (6.25 ng/ml) or rActivin-A (25 ng/ml) for 24 hours. Cells (3 × 10 6 ) from mice of each genotype and stimulation condition (n = 4 per group) were then washed three times with ice-cold PBS before undergoing dry cell pellet storage at −80°C. Cells were lysed in preheated (95°C) 5% SDS/10 mM tris/10 mM tris (2-carboxyethyl) phosphine/5.5 mM 2-chloroacetamide and heated at 95°C for 10 min. Neat trifluoracetic acid (Sigma) was added to hydrolyze the DNA, resulting in a final concentration of 1%. Lysates were quenched with 4 M tris (pH 10), resulting in a final concentration of ~140 mM tris (pH 7). NK cell protein lysates (~60 g) were prepared for mass spectrometry (MS) analysis as described by Dagley et al. (59) . For all experiments with magnetic beads, a 1:1 combination mix of the two types of commercially available carboxylate beads (Sera-Mag SpeedBeads, #45152105050250 and #65152105050250, GE Healthcare) was used. Beads were prepared freshly each time by rinsing with water three times before use and storage at 4°C at a stock concentration of 20 g/l. Carboxylate beads (4 l) were added to all samples together with acetonitrile [ACN; final concentration, 70% (v/v)] and incubated at room temperature for 18 min. Samples were then placed on a magnetic rack, supernatants were discarded, and the beads were washed twice with 70% ethanol and once with neat ACN (180-l washes). ACN was completely evaporated from the tubes using a CentriVap (Labconco) before the addition of 40 l of digestion buffer (10% trifluoroethanol/100 mM NH 4 HCO 3 ) containing Lys-C (Wako, 129-02541) and Trypsin Gold (Promega, V5280) each at a 1:50 enzyme/substrate ratio. Enzymatic digestions proceeded for 1 hour at 37°C using the ThermoMixer C (Eppendorf) shaking at 400 rpm. After the digest, samples were placed on a magnetic rack, the supernatants containing peptides were collected, and an additional elution (50 l) was performed with 2% dimethyl sulfoxide (Sigma) before sonication in a water bath for 1 min. The eluates were pooled together and transferred to the top of pre-equilibrated C18 StageTips (4× plugs of 3 M Empore resin, #2215) for sample cleanup as previously described (60) . The eluates were lyophilized to dryness using a CentriVap (Labconco) before being reconstituted in 30 l of 0.1% formic acid/2% ACN ready for MS analysis.
MS analysis
Peptides (2 l) were separated by reversed-phase chromatography on a 1.6-m C18 fused silica column (inner diameter 75 m, outer diameter 360 m × 25 cm length) packed into an emitter tip (IonOpticks) using a nano-flow high-performance liquid chromatography (HPLC) (M-class, Waters). The HPLC was coupled to an Impact II UHR-QqTOF mass spectrometer (Bruker) using a CaptiveSpray source and nanoBooster at 0.20 bar using ACN. Peptides were loaded directly onto the column at a constant flow rate of 400 nl/min with buffer A (99.9% Milli-Q water and 0.1% formic acid) and eluted with a 90-min linear gradient from 2 to 34% buffer B (99.9% ACN and 0.1% formic acid). Mass spectra were acquired in a data-dependent manner including an automatic switch between MS and MS/MS scans using a 1.5-s duty cycle and 4-Hz MS1 spectra rate followed by MS/MS scans at 8 to 20 Hz dependent on precursor intensity for the remainder of the cycle. MS spectra were acquired between a mass range of 200 and 2000 m/z (mass-to-charge ratio). Peptide fragmentation was performed using collision-induced dissociation. For data analysis, raw files consisting of high-resolution MS/MS spectra were processed with MaxQuant (version 1.5.8.3) for feature detection and protein identification using the Andromeda search engine (61). Extracted peak lists were searched against the Mus musculus database (UniProt, October 2016), as well as a separate reverse decoy database to empirically assess the false discovery rate (FDR) using strict trypsin specificity, allowing up to two missed cleavages. The minimum required peptide length was set to seven amino acids. In the main search, precursor mass tolerance was 0.006 Da and fragment mass tolerance was 40 parts per million (ppm). The search included variable modifications of oxidation (methionine), N-terminal acetylation, the addition of pyroglutamate (at the N termini of glutamate and glutamine), and a fixed modification of carbamidomethyl (cysteine). The "match between runs" option in MaxQuant was used to transfer identifications made between runs on the basis of matching precursors with high mass accuracy (62) . Peptide spectrum matches and protein identifications were filtered using a target-decoy approach at an FDR of 1%.
Seahorse assays
For seahorse assays, NK cells were stimulated overnight (for 20 hours) in medium containing rIL-15 (100 ng/ml) together with the concentrations of rActivin-A or rTGF-1 indicated in the figure legends, washed three times in PBS, and incubated for 3 hours in Seahorse XF Media unbuffered glucose-free Dulbecco's modified Eagle's medium (Seahorse Bioscience) containing rIL-15 (5 ng/ml). Stimulated cells were then transferred to 0.5% gelatin-coated seahorse plates (Seahorse Bioscience), suspended in 160 l of Seahorse XF Media, and then stimulated with 40 l of the same medium containing a final concentration (per well) of 25 mM glucose, 1 M oligomycin, 1.5 M FCCP, 1 mM sodium pyruvate, 1 M antimycin A, and 0.1 M rotenone. OCRs and ECARs were measured every 7 min using a Seahorse XF e 96 analyzer (Seahorse Bioscience).
FST-specificity bioassay
The activin-responsive luciferase reporter A3-Lux or the BMPresponsive luciferase reporter BRE-Lux was used to measure the bioactivity of FST. Human embryonic kidney (HEK) 293 T cells were plated on poly-lysine-coated 24-well plates at a density of 150,000 cells per well. Approximately 24 hours later, the cells were transfected with A3-Lux (25 ng) or BRE-Lux (100 ng) using Lipofectamine 2000 transfection reagent (Invitrogen). Sixteen hours after transfection, the cells were treated with 0.2 nM activin-A, BMP2, or BMP7 together with increasing concentrations of FST (0 to 2 nM). After 16 hours, the cells were harvested in solubilization buffer [1% Triton X-100, 25 mM glycine (pH 7.8), 15 mM MgSO 4 , 4 mM EGTA, and 1 mM dithiothreitol], and luciferase reporter activity was then measured according to standard protocols.
In vivo assays
In vivo models were performed as previously described for intravenous inoculation of 2 × 10 5 or 4 × 10 5 B16F10 cells (49) or systemic MCMV infection with 5 × 10 3 plaque-forming units (PFU) of MCMV-K181 intraperitoneally (53) . Treatments were performed blinded, and the code was revealed with witnesses at the end of the experiments and data analysis: Clinical-grade activin-A inhibitor, FST (provided by Paranta Biosciences Ltd., Melbourne, Australia), was intraperitoneally administrated with daily doses of 10 g per mouse as indicated in the figure legends; neutralizing anti-TGF-1/2/3 antibody clone 1D11.16.8 or the corresponding control immunoglobulin G1 (IgG1) (Bio X Cell) was administrated every 3 days with intraperitoneally administered doses of 500 g per mouse as indicated in the figure legends. At the endpoint of the MCMV infections (day 6 after intraperitoneal viral inoculation), organs were processed for antibody staining and flow cytometric analysis as indicated in the figure legends, and MCMV viral titers in organs were determined by plaque assay using M210B4 cells as previously described (49, 53) .
Statistical analysis
Statistical analysis was performed with GraphPad Prism software v6. The statistical tests used were the unpaired t test, paired t tests for seahorse assays, and the two-way analysis of variance (ANOVA) test for cytotoxicity and proliferation experiments. Error bars represent SEM or SD, as indicated in the figure legends. Levels of statistical significance were expressed as P values: *P < 0.05, **P < 0.01, and ***P < 0.001. For the label-free quantitative proteomics pipeline, statistically significant changes in protein abundance between the RII FL and control groups were identified using a custom-designed, in-house pipeline, as previously described (6), where quantitation was performed at the peptide level. Probability values were corrected for multiple testing using the Benjamini-Hochberg method (63) . Cutoff lines with the function y = −log 10 (0.05) + c/(x − x 0 ) (64) were introduced to identify statistically significantly enriched proteins. c was set to 0.2, whereas x 0 was set to 1, representing proteins with a twofold (log 2 protein ratios of ≥1 or more) or fourfold (log 2 protein ratio of 2) change in protein abundance, respectively.
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